Resistance to antibiotics

Antimicrobial resistance to antibiotics is a public health threat worldwide. Diagnostic tests contribute to reducing the improper use of antibiotics and help ensure they remain effective. They are also a precious tool for epidemiological surveillance and prevention programs. 

The crucial role of diagnostics

Developing these high medical value tests is a priority for bioMérieux. The Company is a pioneer in the development of diagnostic tests for the identification of pathogens, the detection of their potential resistance to antibiotics, as well as antibiotic susceptibility testing to help doctors determine precisely which treatment to prescribe.

 

 

bioMérieux also takes part in programs to educate healthcare professionals and to raise public awareness about the importance of the appropriate use of antibiotics in order to combat this threat.

Partnering with the Fleming Fund

Fleming FundIn 2019, bioMérieux was selected to be a key supplier in a tender process organized by the Fleming Fund, a UK aid investment program to tackle antimicrobial resistance in resource-limited countries.

In 15 countries in Africa and Asia Pacific, the Company’s mission is to equip one clinical reference laboratory and one veterinary reference laboratory with the VITEK® MS and VITEK® 2 systems for pathogen identification and susceptibility testing, and with MYLA® software for data processing.

Renewed support for the GLOBAL-PPS

Since its launch in 2015, bioMérieux has been supporting the Global Point Prevalence Survey (GLOBAL-PPS**), which brings a unique knowledge of antibiotic consumption and antimicrobial resistance worldwide.

Coordinated by Professor Hermann Goossens and Dr. Ann Versporten of the University of Antwerp (Belgium), this survey highlights the importance of in vitro diagnostics and the need to expand the use of diagnostic tests to improve antibiotic prescribing practices worldwide.

In 2019, an additional module on healthcare-associated infections (HAIs) was included into the GLOBAL-PPS to provide additional tools to hospitals.

In 2020, in the health crisis situation, it was decided to collect SARS-CoV-2 data in order to analyze the consolidated information.

 

Sixteen scientific articles about the GLOBAL-PPS have been published since it was launched.

To learn more : watch our video.

CARE, a multi-partner program in China 

The China Against drug REsistance program, initiated in 2013 by the Mérieux Foundation, receives support from bioMérieux, which oversees its implementation. This program, which is based in particular on the GLOBAL-PPS, provides a standardized tool (quality indicators) to help hospitals improve their antimicrobial stewardship programs and control healthcare-associated infections in order to limit the spread of antimicrobial resistance in China.

In 2016, the first point prevalence survey was conducted in four clinical departments of the First Affiliated Hospital of Zhejiang University in Zhejiang Province. In 2019, the CARE program was expanded to 9 hospitals in 8 Chinese provinces. 

Due to the COVID-19 pandemic, no new hospital joined the program in 2020, but one of the nine existing ones was surveyed for the second time.

Collaboration agreement in Ivory Coast

In June 2019, on the occasion of the inauguration of the bioMérieux Training Center in Abidjan for healthcare professionals, we signed a three-year memorandum of understanding with the Ivory Coast. The aim is to fight antimicrobial resistance through the operational implementation of educational, training and communication initiatives.

Since the memorandum was signed and the training center opened, 97 laboratory technicians have received specialized training on blood culture, identification and antibiotic susceptibility testing to help fight antimicrobial resistance.

 

 bioMérieux alongside international bodies 

  • Took part in the launch of the AMR Industry Alliance, a consortium created to drive and measure industry progress and provide sustainable solutions to curb antimicrobial resistance. Mark Miller, bioMérieux’s Corporate Vice President and Chief Medical Officer, sits on the Alliance’s Board of Directors as a representative of the diagnostics industry.
  • Voting member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB);
  • Member of the AdvaMed (Advanced Medical Technology Association) and MedTechEurope working groups;
  • Leader of the French “Antibiorésistance” project of the Industrial and Governmental Health Strategy Committee.
  • Support of CIDRAP’s action (Center for Infectious Disease Research and Policy at the University of Minnesota – United States) in favor of the responsible use of antibiotics.

bioMérieux is the exclusive private sponsor of the Global Point Prevalence Survey. The Company funds the survey but plays no role in the study design, selection, analysis and interpretation of data nor in drafting the report. The data, which are strictly confidential, are stored anonymously at the Coordination Center of the University of Antwerp.